Debioclinic is the clinical research unit of , a global biopharmaceutical
development specialist that in-licenses promising biologics and small molecule drug
candidates. We support the development of Debiopharm's products for global registration.
Debioclinic provides regulatory, biometric, pharmaceutical, clinical and project
management support to relaying on preferred providers partnerships with
contract research organisations (CROs) and others healthcare professional providers.
MILESTONES
1993
Debioclinic was founded in Paris (France) as an international Clinical Research Unit, providing regulatory, biometry, medical and clinical operations to . Its primary preferred therapeutic area was oncology.
1996
Debioclinic conducted the pivotal study for registration of in France for colorectal cancer patients.
1998
Debioclinic conducted the pivotal study for registration of in Europe for colorectal cancer patients.
2006 - 2008
sales represented more than 1.4 Billions € per year, making it a one the best marketed product for sanofi aventis and a leading innovative treatment of colorectal cancer.
2009
Debioclinic, as the clinical development platform of , supports the constant growth of . Since 2006, more than 15 studies were performed worldwide using our EDC system.
In 15 years, Debioclinic has conducted 80 clinical trials (phase I to III) in 20 countries involving more than 6,000 patients.
